AIM ImmunoTech (AIM) Gross Margin (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Gross Margin came in at 81.82% in Q1 2026, up 4432.0% YoY from 1.81% in Q1 2025, and up 190.43% on a QoQ basis from 90.48% in Q4 2025.
AIM ImmunoTech (AIM) Gross Margin (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Gross Margin data on file, last reported at 81.82% in Q1 2026.
- Quarterly Gross Margin rose 4432.0% year-over-year to 81.82% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 29.79% (down 10718.0% YoY) and the FY2025 annual result came in at 45.45%, down 12722.0% from the prior year.
- Gross Margin rose to 81.82% in Q1 2026, from 90.48% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 84.44% in Q4 2024 to a low of 161.54% in Q3 2025.
- A 5-year average of 8.14% and a median of 60.0% in 2025 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2022 — Gross Margin surged 98304 bps — and 2025, when it tumbled 23868 bps.
- Tracing AIM's Gross Margin over 5 years: stood at 130.0% in 2022, then jumped by 163 bps to 81.54% in 2023, then advanced by 4 bps to 84.44% in 2024, then plunged by 207 bps to 90.48% in 2025, then surged by 190 bps to 81.82% in 2026.
- The last three Gross Margin figures came in at 81.82% (Q1 2026), 90.48% (Q4 2025), and 161.54% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | AIM ImmunoTech | 4.34 Mn | -5.62 Mn | 21,000.00 | 80.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.77% |
| Mar 31, 2026 | 81.82% |
| Dec 31, 2025 | -90.48% |
| Sep 30, 2025 | -161.54% |
| Jun 30, 2025 | 60.00% |
| Mar 31, 2025 | 37.50% |
| Dec 31, 2024 | 84.44% |
| Sep 30, 2024 | 77.14% |
| Jun 30, 2024 | 84.00% |
| Mar 31, 2024 | 80.00% |
| Dec 31, 2023 | 81.54% |
| Sep 30, 2023 | 34.78% |
| Jun 30, 2022 | -130.00% |
| Mar 31, 2022 | -133.33% |
| Dec 31, 2021 | -252.00% |
| Sep 30, 2021 | -375.76% |
| Jun 30, 2021 | -1,113.04% |
| Mar 31, 2021 | -746.43% |
| Dec 31, 2020 | -371.43% |
| Sep 30, 2020 | -466.67% |